Furthermore, it has been reported that IFNα2 decreases proliferation of PCa cells and several other tumors in vitro and in vivo and IFNα2 treatment is one of the few FDA-approved cancer immunotherapeutics (Hobeika et al. 1999, Kirkwood 2002, Bracarda et al. 2010). This evidence concerns the gene IFNA2 and cancer.